open access

Vol 22, No 1 (2019)
Original articles
Published online: 2019-01-31
Submitted: 2018-10-05
Accepted: 2019-01-18
Get Citation

Comparison of 18F-fluoroethylo-L-thyrosine PET/CT and MR in the diagnosis of primary brain tumors referred to radiation therapy

Paulina Cegla, Krystyna Adamska, Ewa Wierzchosławska, Michał Smoleń, Witold Cholewiński
DOI: 10.5603/NMR.2019.0002
·
Nucl. Med. Rev 2019;22(1):14-17.

open access

Vol 22, No 1 (2019)
Original articles
Published online: 2019-01-31
Submitted: 2018-10-05
Accepted: 2019-01-18

Abstract

BACKGROUND: The diagnostic efficacy of 18F-FDG-PET imaging in brain tumors is markedly reduced due to high glucose metabolism in normal brain tissue. This requires further research for more sensitive and specific tracers. 18F-fluoroethylo-L-thyrosine (18F-FET) is an interesting PET radiotracer, which shows promising results in patients with brain tumors. The aim of this study was to compare 18F-fluoroethylo-L-thyrosine PET/CT and MRI in the diagnosis of primary brain tumors referred to radiation therapy.

MATERIAL AND METHODS: Thirteen patients (5M, 8F) with mean age of 56y ± 13 and histologically confirmed primary braintumors were investigated. The MRI scans were performed on MRI 1.5T scanner with FSE, DWI method, T1, T2 and FLAIR sequence. The examination was performed using brain protocol for 35 minutes and prior to PET imaging. The PET scans were performed 20–40 min after intravenous injection of 160 MBq of 18F-FET. Scans were acquired on Gemini TF PET/CT scanner using 3D brain imaging protocol for 10 minutes acquisition time. The reconstructed PET images were evaluated on a dedicated EBW workstation with Time-of-Flight reconstruction algorithms. On reconstructed images, the tumor borders were drawn using dedicated software, based on various threshold values and tumor borders and volumes were calculated on each nuclear image and compared with the volume calculated on the diagnostic MRI. For statistical analysis the t-test was used.

RESULTS: 18F-FET-PET imaging in total showed more abnormal lesions that MRI; however, the difference was not significant (p > 0.05). There were two patients with lesions detected only on the MRI study and 4 patients with abnormal tracer uptake within the brain in 18F-FET study with no correlation in the MRI study. 18F-FET-PET method showed 30 lesions in 11 patients with mean SUVmax value of 2.33 (range from 1.6 to 3.5). Based on 70% threshold cutoff value, the mean volume of brain focus was calculated on at 31.15 ± 26.89 mm3 and was in concordance with mean lesion volume measured on the MRI scan 31.51 ± 34.97 mm3. For radiation planning purposes other threshold values, as well as gradient based methods were evaluated on 18F-FET-PET imaging.

CONCLUSION: PET/CT imaging with 18F-fluoroethylo-L-thyrosine is complementary to MRI in the diagnosis of primary brain tumors referred to radiation therapy.

Abstract

BACKGROUND: The diagnostic efficacy of 18F-FDG-PET imaging in brain tumors is markedly reduced due to high glucose metabolism in normal brain tissue. This requires further research for more sensitive and specific tracers. 18F-fluoroethylo-L-thyrosine (18F-FET) is an interesting PET radiotracer, which shows promising results in patients with brain tumors. The aim of this study was to compare 18F-fluoroethylo-L-thyrosine PET/CT and MRI in the diagnosis of primary brain tumors referred to radiation therapy.

MATERIAL AND METHODS: Thirteen patients (5M, 8F) with mean age of 56y ± 13 and histologically confirmed primary braintumors were investigated. The MRI scans were performed on MRI 1.5T scanner with FSE, DWI method, T1, T2 and FLAIR sequence. The examination was performed using brain protocol for 35 minutes and prior to PET imaging. The PET scans were performed 20–40 min after intravenous injection of 160 MBq of 18F-FET. Scans were acquired on Gemini TF PET/CT scanner using 3D brain imaging protocol for 10 minutes acquisition time. The reconstructed PET images were evaluated on a dedicated EBW workstation with Time-of-Flight reconstruction algorithms. On reconstructed images, the tumor borders were drawn using dedicated software, based on various threshold values and tumor borders and volumes were calculated on each nuclear image and compared with the volume calculated on the diagnostic MRI. For statistical analysis the t-test was used.

RESULTS: 18F-FET-PET imaging in total showed more abnormal lesions that MRI; however, the difference was not significant (p > 0.05). There were two patients with lesions detected only on the MRI study and 4 patients with abnormal tracer uptake within the brain in 18F-FET study with no correlation in the MRI study. 18F-FET-PET method showed 30 lesions in 11 patients with mean SUVmax value of 2.33 (range from 1.6 to 3.5). Based on 70% threshold cutoff value, the mean volume of brain focus was calculated on at 31.15 ± 26.89 mm3 and was in concordance with mean lesion volume measured on the MRI scan 31.51 ± 34.97 mm3. For radiation planning purposes other threshold values, as well as gradient based methods were evaluated on 18F-FET-PET imaging.

CONCLUSION: PET/CT imaging with 18F-fluoroethylo-L-thyrosine is complementary to MRI in the diagnosis of primary brain tumors referred to radiation therapy.

Get Citation

Keywords

Radiotherapy; brain tumor; positron emission tomography; 18F-fluoroethylo-L-thyrosine; magnetic resonance.

About this article
Title

Comparison of 18F-fluoroethylo-L-thyrosine PET/CT and MR in the diagnosis of primary brain tumors referred to radiation therapy

Journal

Nuclear Medicine Review

Issue

Vol 22, No 1 (2019)

Pages

14-17

Published online

2019-01-31

DOI

10.5603/NMR.2019.0002

Bibliographic record

Nucl. Med. Rev 2019;22(1):14-17.

Keywords

Radiotherapy
brain tumor
positron emission tomography
18F-fluoroethylo-L-thyrosine
magnetic resonance.

Authors

Paulina Cegla
Krystyna Adamska
Ewa Wierzchosławska
Michał Smoleń
Witold Cholewiński

References (15)
  1. Smits A, Baumert BG. The Clinical Value of PET with Amino Acid Tracers for Gliomas WHO Grade II. Int J Mol Imaging. 2011; 2011.
  2. Herholz K, Pietrzyk U, Voges J, et al. Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg. 1993; 79(6): 853–858.
  3. Goldman S, Levivier M, Pirotte B, et al. Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography-guided stereotactic biopsy. Cancer. 1996; 78(5): 1098–1106.
  4. Dunet V, Rossier C, Buck A, et al. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl Med. 2012; 53(2): 207–214.
  5. Kracht LW, Miletic H, Busch S, et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004; 10(21): 7163–7170.
  6. Rachinger W, Goetz C, Pöpperl G, et al. Positron Emission Tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus Magnetic Resonance Imaging in the Diagnosis of Recurrent Gliomas. Neurosurgery. 2005; 57(3): 505–511.
  7. Suchorska B, Jansen NL, Linn J, et al. German Glioma Network. Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology. 2015; 84(7): 710–719.
  8. Jansen NL, Suchorska B, Wenter V, et al. Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma. J Nucl Med. 2015; 56(1): 9–15.
  9. Pirotte BJM, Levivier M, Goldman S, et al. Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery. 2009; 64(3): 471–81; discussion 481.
  10. Piroth MD, Holy R, Pinkawa M, et al. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiother Oncol. 2011; 99(2): 218–224.
  11. Grosu AL, Weber WA, Franz M, et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005; 63(2): 511–519.
  12. Grosu AL, Weber WA, Astner ST, et al. 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2006; 66(2): 339–344.
  13. Miwa K, Shinoda J, Yano H, et al. Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry. 2004; 75(10): 1457–1462.
  14. Nuutinen J, Sonninen P, Lehikoinen P, et al. Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys. 2000; 48(1): 43–52.
  15. Kläsner B, Buchmann N, Gempt J, et al. Early [18F]FET-PET in Gliomas after Surgical Resection: Comparison with MRI and Histopathology. PLoS One. 2015; 10(10): e0141153.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl